A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Evolocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Amgen
- 28 Aug 2019 Planned primary completion date changed from 23 Oct 2020 to 9 Oct 2020.
- 09 May 2019 Status changed from not yet recruiting to recruiting.
- 18 Dec 2018 Planned End Date changed from 25 Aug 2020 to 23 Oct 2020.